MWNA
ZNTL icon

Marshall Wace North America’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Marshall Wace North America’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-59,629
Closed -$3.1M – 1817
2020
Q4 		$3.1M Hold
59,629
– – 0.01% 646
2020
Q3 		$1.95M Hold
59,629
– – 0.01% 600
2020
Q2 		$2.86M Buy
+59,629
New +$2.29M 0.02% 487

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Marshall Wace North America's ZNTL Position: Q1 2021 in Review

Marshall Wace North America sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2021, closing a stake of 59,629 shares — an estimated $3.1M sold.

Marshall Wace North America first reported a position in ZNTL in Q2 2020 and held it in 3 quarters. The position peaked at $3.1M in Q4 2020. 95 funds tracked by Wall St. Rank hold ZNTL as of Q1 2021.

  • Marshall Wace North America reported no remaining Zentalis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 59,629 Zentalis Pharmaceuticals shares in Q1 2021, an estimated $3.1M.
  • Marshall Wace North America first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Marshall Wace North America's Zentalis Pharmaceuticals position peaked at $3.1M in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.